|
Retinoblastoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Retinoblastoma (RB) is a childhood eye tumor, caused by the RB1 gene mutation.
|
31781967 |
2020 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
To directly investigate the effects of PR isoform expression on the breast cancer proteome, both in the presence and absence of progestin, PRA and PRB were independently stably expressed in T47DC42 PR-null breast cancer cells using a doxycycline (Dox)-regulated promoter.
|
31809870 |
2020 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
To directly investigate the effects of PR isoform expression on the breast cancer proteome, both in the presence and absence of progestin, PRA and PRB were independently stably expressed in T47DC42 PR-null breast cancer cells using a doxycycline (Dox)-regulated promoter.
|
31809870 |
2020 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Advanced-stage HCC (BCLC B/C) showed higher frequencies of splicing factor 3b subunit 1 (SF3B1) (P = 0.0003), TP53 (P = 0.0006), and RB Transcriptional Corepressor 1 mutations (P = 0.03).
|
31206197 |
2020 |
|
Hypoglycemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
5) the sensitivity for the composite adverse perinatal outcome varied substantially among standards (15% for NICHD to 32% for FMF) given mostly to differences in the FPR, and they subsided when the FPR was set to the same value (10%); 6) the comparison of the AUC revealed a significant improvement for the PRB/NICHD (AUC=0.70) compared to Hadlock (AUC=0.66) and FMF (AUC=0.64) standards for the prediction of perinatal mortality; complementarily, the evaluation of the partial AUC (FPR<10%) revealed that the INTERGROWTH-21 standard had an advantage over the Hadlock standard for NICU admissions and mechanical ventilation (all, p<0.05).
|
31006913 |
2020 |
|
Retinoblastoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The der(X) region harboring the RB1 gene was inactivated in a subset of somatic cells, including the retinal cells, in the patient subject which acted as the first hit in the development of her retinoblastoma.
|
31806026 |
2019 |
|
Retinoblastoma
|
0.800 |
PosttranslationalModification
|
disease |
BEFREE |
Retinoblastoma (RB), which represents the most common childhood eye cancer, is caused by biallelic inactivation of RB1 gene.
|
30427563 |
2019 |
|
Retinoblastoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The retinoblastoma RB1 gene has been identified in the 80s as the first tumor suppressor.
|
31176618 |
2019 |
|
Retinoblastoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
This study might be an important report on emphazing the mutational status of other genes in patients without RB1 gene mutations and having high risk for developing Rb.
|
31207142 |
2019 |
|
Retinoblastoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Retinoblastoma (Rb) results from biallelic inactivation of the RB1 gene.
|
30031154 |
2019 |
|
Familial Retinoblastoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Erratum to: "Monoallelic germline methylation and sequence variant in the promoter of the RB1 gene: a possible constitutive epimutation in hereditary retinoblastoma".
|
28331555 |
2019 |
|
Neoplasm Metastasis
|
0.360 |
AlteredExpression
|
phenotype |
BEFREE |
Additionally, resveratrol treatment inhibited SG-mediated Rbfox2 localization, further inhibiting RB1 protein expression, and inhibited specific Rbfox2 localization to the cytoplasm in melanoma B16-F10 cells, thereby effectively inhibiting metastasis and tumor growth ability.
|
31028247 |
2019 |
|
Neoplasm Metastasis
|
0.360 |
Biomarker
|
phenotype |
BEFREE |
Interestingly, ectopic expression of miR-200b in the Caki-1 and OSRC-2 cell lines suppresses cell migration and invasion in vitro as well as tumor metastases in vivo.
|
31130475 |
2019 |
|
Acute erythroleukemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genomic subtyping and therapeutic targeting of acute erythroleukemia.
|
30926971 |
2019 |
|
Acute erythroleukemia - M6a subtype
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genomic subtyping and therapeutic targeting of acute erythroleukemia.
|
30926971 |
2019 |
|
Acute myeloid leukemia FAB-M6
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genomic subtyping and therapeutic targeting of acute erythroleukemia.
|
30926971 |
2019 |
|
Acute erythroleukemia - M6b subtype
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genomic subtyping and therapeutic targeting of acute erythroleukemia.
|
30926971 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The oncogenic effect of HPV16-E7 relies on its binding to the tumor suppressor pRb protein leading to a dysregulated cell duplication.
|
31806970 |
2019 |
|
Neoplasms
|
0.200 |
PosttranslationalModification
|
group |
BEFREE |
These effects appear to be mediated by the increase of p21 <sup>waf1</sup> and p27 <sup>Kip1</sup> , associated with a reduction of Cyclin D1 and Rb1 protein phosphorylation, and involve the downregulation of key molecules responsible for tumor development, that is, Notch1, Sox2, Stat3, and Survivin.
|
30701538 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
We also discuss the subtype of retinoblastoma driven by the MYCN oncogene more commonly associated with neuroblastoma, and consider trilateral retinoblastoma, in which an intracranial tumor arises along with ocular tumors in patients with germline RB1 gene mutations.
|
29314142 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The retinoblastoma RB1 gene has been identified in the 80s as the first tumor suppressor.
|
31176618 |
2019 |
|
Tumor Progression
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
RBP fox-1 homolog 2 (Rbfox2), a component of SGs, binds to retinoblastoma 1 (RB1) mRNA, which is closely related to cancer progression; however, the role of Rbfox2 in cancer progression remains largely unknown.
|
31028247 |
2019 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Interestingly, ectopic expression of miR-200b in the Caki-1 and OSRC-2 cell lines suppresses cell migration and invasion in vitro as well as tumor metastases in vivo.
|
31130475 |
2019 |
|
Glioma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Eight genes [(GTPase NRas (NRAS), calcium/calmodulin‑dependent protein kinase type II subunit Gamma (CAMK2G), platelet‑derived growth factor receptor alpha (PDGFRA), calmodulin 3 (CALM3), cyclin‑dependent kinase 6 (CDK6), calcium/calmodulin‑dependent protein kinase type II subunit beta (CAMK2B), retinoblastoma‑associated protein (RB1) and protein kinase C beta type (PRKCB)] that were centralized in the glioma pathway were selected for CMap analysis.
|
30816530 |
2019 |
|
Malignant neoplasm of lung
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
EGFR/TP53/RB1-mutant lung cancers are at unique risk of histologic transformation, with 25% presenting with de novo SCLC or eventual small cell transformation.
|
31228622 |
2019 |